Novartis Licenses Abogen’s mRNA-Encoded T Cell Engager in Deal Worth Up to $7.8 Billion

What happened

Novartis agreed on Friday, Oct. 2, to license an mRNA-based T cell engager from Abogen, a Suzhou, China-based biotech, in a deal worth up to $7.8 billion. According to BioSpace, Novartis will pay $575 million upfront, and Abogen is eligible for up to about $7.2 billion in development, regulatory and commercial milestones, plus royalties.

The agreement also gives Novartis an exclusive option to license a set number of additional therapies from Abogen’s proprietary RNA platform.

Deal and asset details

• Upfront: $575 million.
• Milestones: Up to about $7.2 billion.
• Royalties: On future sales.
• Lead asset: ABO2203, an mRNA candidate that gives the body the genetic code to produce a CD3xCD19 T cell engager designed to deplete disease-causing B cells.
• Option: Exclusive rights to license additional programs from Abogen’s RNA platform.

The companies cited potential in autoimmune diseases but did not name target indications, and Novartis declined to disclose them. Abogen takes an AI-centric approach to mRNA design, formulation and manufacturing, according to BioSpace.

Abogen argues that the in vivo approach may lower the risk of cytokine release syndrome, a common and sometimes severe side effect of T cell engagers. In April, first-in-human data from nine patients with relapsed or refractory B-cell non-Hodgkin lymphoma showed no cases of cytokine release syndrome, no dose-limiting toxicities and no neurological complications linked to immunotherapy, with objective response rates reaching 100% at the highest dose level, according to Abogen.

Why it matters for the sector

B-cell depletion has become one of the most closely watched strategies in autoimmune disease. CAR-T therapies and T cell engagers that target CD19 have shown the potential to reset the immune system in conditions such as lupus, prompting a wave of investment. Delivering a T cell engager as mRNA, so that the patient’s own cells produce the drug, is an attempt to combine potency with easier administration and potentially better safety.

The deal is one of the largest licensing agreements with a China-based biotech this year by headline value. Novartis chief executive Vas Narasimhan said on the company’s second-quarter call in July that its strategy is to go wherever the leading science is, and BioSpace noted that Novartis recently licensed a radioligand therapy from BoomRay for up to $900 million.

The agreement also comes as Novartis faces pressure on several fronts. In September, the company disclosed late-stage setbacks for pelacarsen and for del-desiran, and BioSpace has reported on investor scrutiny of its board. The company also suspended several studies of its CAR-T therapy rapcabtagene autoleucel after three deaths, according to BioSpace. A large upfront commitment to a new modality in autoimmunity signals that Novartis is continuing to invest in the area despite those setbacks.

For Abogen, a company that rose to prominence during the COVID-19 pandemic, the deal provides substantial upfront cash and validation for applying its mRNA platform beyond vaccines.

The structure of the agreement, with a large upfront payment and an option on further programs, gives Novartis both a lead asset and access to a platform. That combination is increasingly common in licensing deals with Chinese biotechs, as buyers seek repeatable sources of new candidates rather than single molecules.

Because the early data come from nine patients in lymphoma, much remains to be learned about how the approach performs in autoimmune diseases, where safety expectations are especially high.

What to watch

• Disclosure of target autoimmune indications for ABO2203.
• Further clinical data, particularly on safety in larger patient groups.
• Novartis’s use of its option on additional Abogen programs.
• Competing in vivo CAR-T and mRNA-encoded antibody programs from other developers.
• Policy developments affecting licensing deals with China-based companies.

Sources: BioSpace, BioPharma Dive

How an mRNA-Encoded T Cell Engager Works

A conventional T cell engager is manufactured as a protein in large bioreactors, purified and infused into the patient. An mRNA-encoded version takes a different path.

1. Packaging. The mRNA instructions for the engager are enclosed in lipid nanoparticles, tiny fat-based particles that protect the RNA and help it enter cells.
2. Delivery. After administration, the particles are taken up by cells, often primarily in the liver.
3. Production. Those cells read the mRNA and produce the engager protein, releasing it into the bloodstream.
4. Action. One arm of the engager binds CD3 on T cells and the other binds CD19 on B cells, bringing them together so the T cells destroy the B cells.
5. Decline. mRNA breaks down naturally over time, so production tapers off unless further doses are given.

Because the protein is made gradually rather than infused all at once, developers hypothesize that levels may rise more smoothly, which could influence side effects such as cytokine release syndrome. That remains to be established in larger studies.

Why Depleting B Cells Can Help in Autoimmune Disease

In many autoimmune diseases, B cells contribute by producing autoantibodies that attack the body’s own tissues and by helping activate other immune cells. Older B-cell therapies, such as CD20 antibodies, reduce circulating B cells but may leave some populations in tissues untouched. CD19 is present on a broader range of B-lineage cells, so deep CD19-directed depletion is being explored as a way to more thoroughly reset the B-cell compartment. Early research has raised hopes that, after B cells regrow, some patients may remain in remission without ongoing therapy. Whether that holds over time is still being studied.

The Trade-Offs Developers Must Manage

• Safety expectations. Autoimmune patients may have lower tolerance for serious side effects than people with advanced cancer.
• Infection risk. Removing B cells can weaken defenses against infections and affect vaccine responses.
• Dose control. With in vivo production, how much protein each patient makes can vary.
• Durability. Developers must determine how many doses are needed and how long effects last.

Questions Readers Ask

Is this related to mRNA vaccines?

It uses similar delivery technology, but the goal is to have the body produce a therapeutic protein rather than to train the immune system against an infection.

What does a “100% objective response rate” mean in a small study?

Every patient at that dose level showed measurable tumor shrinkage. With very few patients, such figures are preliminary and can change as more people are treated.

Why include an option on more programs?

An option lets the buyer secure access to future candidates from the same platform without committing to them today. If the lead program performs well, the buyer can expand the relationship on pre-agreed terms.

This article is for general information only and is not medical or investment advice. Patients should consult their own physicians.